0.00Open0.50Pre Close0 Volume2 Open Interest7.50Strike Price0.00Turnover0.00%IV5.68%PremiumDec 6, 2024Expiry Date0.07Intrinsic Value100Multiplier-4DDays to Expiry0.43Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma15.14Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Recursion Pharmaceuticals Stock Discussion
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class Cdk7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
No comment yet